investingreview.org logo
Avoid Fraud, Get The Facts, And Find The Best
Nothings Found.

Crestwood Advisors Group LLC Q4 2022 vs. Q1 2023 13F Holdings Comparison

Ava Hoppe | 13 May, 2023

Crestwood Advisors Group LLC has recently released its Q4 2022 vs. Q1 2023 13F Holdings Comparison Report, revealing some significant changes in its holdings of funds. Let's take a closer look at Crestwood Advisors Group LLC's investment strategy, the restructuring of its investment portfolio, and what investors can learn from these changes.

Crestwood Advisors Group LLC is an independently-owned investment advisory firm that manages around $31 billion in assets. Its clients are primarily institutional investors, including charitable foundations, endowments, and pension funds. Crestwood Advisors aims to provide its clients with long-term capital appreciation by investing in high-quality, growth-oriented companies in both domestic and international markets.

Top-performing tech stocks remain an essential part of Crestwood Advisors' investment strategy. The firm has significantly reduced its holdings in Apple (AAPL) and Microsoft (MSFT) by 5.5% and 2.4%, respectively. Despite the reduction, Crestwood Advisors still holds Apple shares worth $235 million and Microsoft shares worth $183 million, indicating that the firm believes these companies have strong long-term growth potential.

The fund has also reduced its holdings in Amazon (AMZN), which is not surprising, given its recent controversies and regulatory scrutiny. Crestwood Advisors sold off 10.7% of its Amazon shares because of the negative news surrounding the company. Similarly, the firm decreased its holdings in Johnson & Johnson (JNJ) by 3.6% due to the pharmaceutical company's ongoing legal troubles.

In contrast, Crestwood Advisors increased its holdings in Honeywell International (HON) by 6.3% and added more shares of Danaher Corporation (DHR) by 61.5%, indicating a bullish outlook on these companies.

The firm also added several new positions to its portfolio, including a massive $327 million investment in Thermo Fisher Scientific (TMO). This investment likely indicates the firm's confidence in the healthcare and life sciences sector to continue growing in the coming years.

Overall, Crestwood Advisors' investment strategy seems to be paying off, with the firm managing to achieve significant capital gains for its clients. By focusing on high-quality companies with strong growth potential, Crestwood Advisors has managed to position itself to weather market turbulence while capitalizing on opportunities for growth.

Investors can learn from Crestwood Advisors' approach and take a long-term view of their portfolios. Instead of reacting impulsively to short-term market fluctuations or news events, Crestwood Advisors focuses on building a robust, diversified portfolio of high-quality, growth-oriented companies. By taking this approach, investors can benefit from long-term capital appreciation while minimizing risk.

Many people have been burned by frauds and Ponzi schemes. So we created this website to help you, the potential investor, get the facts, find the best, and avoid fraud and Ponzi schemes.

All information provided on this website is provided without warranty and for informational purposes only.
InvestingReview.org does not provide investment advice. InvestingReview.org is not an investment adviser and is not endorsed by or affiliated with any U.S. or non-U.S. regulatory agency.


Recently Searched Firms

Please note: Search data is accumulated by 3rd party and refreshed once per day.

Copyright © 2023 by InvestingReview.org / All Rights Reserved.